Cancer Models Forum

Posted by Repositive, March 2019

How to overcome the challenges biopharmas face when sourcing preclinical cancer models

A recent meta-analysis of clinical trials put the success rate for therapies in cancer indications progressing from first-in-human to approval at just 3.4%. That means a staggering 96.6% of cancer therapies fail during the clinical stages of drug development. But why?

Finding the right preclinical cancer models is a challenge

One of the fundamental challenges biopharma researchers face is finding the right preclinical cancer models for their projects. As cancer drug development accelerates towards personalised treatments, there is now an increasing need for biopharmas to source cancer models with specific molecular and genomic characteristics, which can more accurately predict clinical outcomes. But with such a large variety of model types and technologies available worldwide and no standardisation of model data between providers, it has previously been difficult to find and compare cancer models from different Contract Research Organisations (CROs). So how can researchers ensure they are using the best available model for their research?

In this blog post we explore two initiatives that are helping to advance new cancer treatments to the clinic:

1. Innovative marketplaces for preclinical cancer models

Over the last few years, innovative marketplaces have been created to help overcome this fragmentation and provide biopharma researchers with inventories of preclinical cancer models from providers across the globe. PDX Finder, for example, is an online platform cataloguing patient-derived xenografts models and their associated data from different suppliers. Meanwhile, Ximbio offers a portfolio of research reagents and supplies for biotech and pharma companies, including hybridomas, cell lines and mouse models. The world’s largest database of preclinical cancer models, known as the Cancer Models Directory, enables biopharma researchers to search over 5,400 models from specialist preclinical oncology CROs around the world.

2. Expert and tailored cancer model search services

In addition, tailored cancer model search services are now available where oncology and bioinformatics experts are on hand to further support translational oncology researchers in finding their next model. Through personalised search services, experts can work with biopharmas to refine their model requirements and find a list of providers with models that match their specifications – all in complete confidence. By using a tailored search service, such as the Cancer Models Scout service, search times can be reduced from months down to an average of just a few weeks. This not only ensures that researchers working in biotech and pharma can get started on their projects much quicker, saving both time and money, but it crucially helps to accelerate the development of precision cancer therapies to the clinic for the benefit of patients.

To keep up-to-date with the latest developments and hot topics in translational oncology, sign up to our mailing list!

Sign up to mailing list button

This blog was originally written by the Repositive Team for the BioIndustry Association UK website

Posted by
Repositive

Repositive

Repositive Press Team
See all Repositive's posts